In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

In the fourth quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound.

The results come after the maker of weight-loss drugs Zepbound and Mounjaro in January lowered expectations for its fourth-quarter sales. Eli Lilly (LLY) is set to report fourth-quarter earnings ...

Doctors warn about their physical side effects, but they can also have unexpected effects on intimacy. Jeanne and Javier, who have been married for 15 years.Credit...Katherine Wolkoff for The New ...

The biggest selling weight-loss drugs from now until 2030 will unquestionably be Eli Lilly’s (NYSE:LLY) tirzepatide, marketed and sold as Mounjaro (diabetes) and Zepbound (obesity), and Novo ...

Weaker than expected data from the trial was a blow to Novo's ambitions to find a more powerful competitor to Lilly's Zepbound, also known as Mounjaro. CagriSema combines semaglutide, the active ...

One Eli Lilly-backed trial showed that Zepbound was better than Wegovy at helping users cut weight. The specter of fresh tariffs under the Donald Trump administration, in addition to a showdown ...